Application of angelica sinensis in resisting skin atrophy
By using a combination of angelica sinensis and its extracts with other active ingredients, the problem of skin atrophy caused by glucocorticoids is solved, skin thickness is increased and skin function is enhanced, making it suitable for the preparation of drugs, health products and cosmetics that improve skin atrophy.
Patent Information
- Application Number
- CN202310600531.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
AI Technical Summary
Existing technologies are insufficient to effectively treat skin atrophy caused by glucocorticoids, especially skin atrophy caused by topical glucocorticoids, which leads to decreased skin barrier function and increased moisture loss.
By using the traditional Chinese medicine *Angelica sinensis* and its extracts, the proliferation capacity of epidermal cells is restored and the skin's anti-atrophy ability is enhanced by increasing the amount of extracellular matrix such as collagen and glycosaminoglycans. Specific methods include combining water extracts and organic solvent extracts of *Angelica sinensis* with other active ingredients such as vitamin A and vitamin C to prepare drugs, health products, or cosmetics.
It significantly increases skin thickness, enhances skin mechanical strength and anti-atrophy ability, restores epidermal cell proliferation ability, and improves skin atrophy caused by glucocorticoids.
Smart Images

Figure HDA0004248792720000011 
Figure HDA0004248792720000012 
Figure HDA0004248792720000021
Abstract
Description
Technical Field
[0001] The invention relates to the field of medicine, and in particular to use of a traditional Chinese medicine, Radix Angelicae Pubescentis, and an extract thereof in improving skin atrophy caused by glucocorticoids. Background Art
[0002] As the largest organ in the human body, the skin can not only effectively protect the various organs and tissues inside the body from adverse stimuli from the external environment, including physical and chemical stimuli, harmful pathogenic microorganisms, etc., but also has multiple physiological functions such as regulating body temperature, secretion and excretion, and sensing external stimuli. Therefore, the skin plays an indispensable role in the growth and development of an individual.
[0003] Glucocorticoids (GC) are steroid hormones widely used to treat inflammation, autoimmune diseases and cancer, and play an important role in clinical treatment. However, many adverse reactions occur in the process of topical glucocorticoid treatment, among which skin atrophy is the most common adverse reaction. Glucocorticoid-induced skin atrophy is mainly manifested by damage to the epidermis, dermis and extracellular matrix structure of the skin, resulting in reduced barrier function of the skin and increased water loss, making the skin dry and loose. At the same time, glucocorticoids interfere with protein synthesis and degradation in skin cells, reduce skin thickness and cause skin metabolic dysfunction. In short, glucocorticoid-induced skin atrophy will have many adverse effects on the normal structure and function of the skin.
[0004] As an important part of my country's medical treasure house, Chinese herbal medicine not only occupies an important position in the history of my country's medical development, but also has made significant contributions to promoting the development of world medicine. Based on the Chinese herbal medicine library, screening and searching for drugs with good activity, high safety and strong universality that can improve skin atrophy caused by topical glucocorticoids has great potential and broad development prospects in future clinical medication.
[0005] Therefore, there is a need in the art to develop new Chinese herbal medicines that can effectively treat skin atrophy caused by glucocorticoids. Summary of the invention
[0006] The main purpose of the present invention is to provide a Chinese herbal medicine, namely, Xigui, which can improve skin atrophy caused by glucocorticoids (especially topical glucocorticoids). Specifically, the present invention relates to the use of the Chinese herbal medicine Xigui in the preparation of medicines, health products or cosmetics for improving skin atrophy.
[0007] In the first aspect of the present invention, there is provided a use of an active ingredient for preparing a preparation or composition for regulating skin function; wherein the active ingredient is Radix Angelicae Pubescentis or Radix Angelicae Pubescentis extract.
[0008] In another preferred embodiment, the skin conditioning function is to improve skin atrophy.
[0009] In another preferred embodiment, the skin atrophy refers to skin atrophy caused by non-aging factors.
[0010] In another preferred embodiment, the skin atrophy refers to skin atrophy of people aged 50 years old, preferably, skin atrophy of people aged 40 years old; more preferably, skin atrophy of people aged 30 years old; most preferably, skin atrophy of people aged 20 years old.
[0011] In another preferred embodiment, the skin atrophy refers to atrophy caused by physical or chemical factors.
[0012] In another preferred embodiment, the physical factor refers to skin atrophy caused by light and / or radiation.
[0013] In another preferred embodiment, the skin atrophy caused by chemical factors refers to skin atrophy caused by drugs.
[0014] In another preferred embodiment, the drug includes glucocorticoid.
[0015] In another preferred embodiment, the skin atrophy refers to skin atrophy caused by glucocorticoids.
[0016] In another preferred embodiment, the skin atrophy is caused by oral or topical glucocorticoids.
[0017] In another preferred embodiment, the glucocorticoid is selected from the following group: hydrocortisone, methylprednisolone, prednisone, dexamethasone, beclomethasone, betamethasone, hydrocortisone valerate, doprednisolone, prednicarbate, hydrocortisone butyrate, methylprednisolone acetate, triamcinolone acetonide, betamethasone valerate, mometasone furoate, fluticasone propionate, fluocinolone acetate, fluocinolone acetonide, clobetasol propionate, or a combination thereof.
[0018] In another preferred embodiment, the skin atrophy refers to atrophy of the dermis and / or atrophy of the epidermis.
[0019] In another preferred embodiment, the skin atrophy refers to a decrease in the thickness of the dermis by ≥15%; preferably, a decrease by ≥25%; more preferably, a decrease by ≥40%.
[0020] In another preferred embodiment, the skin atrophy refers to a decrease in the thickness of the epidermis by ≥15%; preferably, a decrease by ≥25%; more preferably, a decrease by ≥50%.
[0021] In another preferred embodiment, the skin atrophy refers to a 10% decrease in the amount of collagen in the extracellular matrix; preferably, a decrease of ≥15%; more preferably, a decrease of ≥20%.
[0022] In another preferred embodiment, the Xigui extract is selected from the following group: a water extract of Xigui, an organic solvent extract of Xigui, or a combination thereof.
[0023] In another preferred embodiment, the organic solvent for extracting the active ingredient is selected from the following group: ethanol, petroleum ether, ethyl acetate or a combination thereof.
[0024] In another preferred embodiment, the composition or preparation is used for one or more purposes selected from the following group:
[0025] (i) increase the mechanical strength of the skin; and
[0026] (ii) enhancing the skin's ability to resist atrophy; and
[0027] (iii) Restoration of epidermal cell proliferation capacity.
[0028] In another preferred embodiment, the composition or preparation is used to increase the thickness of the dermis.
[0029] In another preferred embodiment, the composition or preparation is used to increase the thickness of the dermis by 10%, 15%, 20% or 25%.
[0030] In another preferred embodiment, the composition or preparation is used to increase the thickness of the epidermis.
[0031] In another preferred embodiment, the composition or preparation is used to increase the thickness of the epidermis by 10%, 15%, 20% or 25%.
[0032] In another preferred embodiment, the increasing the mechanical strength of the skin includes increasing the level of skin extracellular matrix.
[0033] In another preferred embodiment, the extracellular matrix includes: collagen, elastin, glycosaminoglycan, proteoglycan, or a combination thereof.
[0034] In another preferred embodiment, the enhancing the anti-atrophy ability of epidermal cells comprises reducing the expression level of REDD1 protein.
[0035] In another preferred embodiment, the restoration of epidermal cell proliferation ability includes enhancing the expression level of Ki67 protein in skin cells.
[0036] In another preferred embodiment, the skin or epidermal cells are skin or epidermal cells treated with glucocorticoid.
[0037] In another preferred embodiment, the skin is normal skin and / or atrophic skin.
[0038] In another preferred embodiment, the composition is a pharmaceutical composition, a cosmetic composition, a dietary supplement, a food composition, or a health product composition.
[0039] In another preferred embodiment, the composition or preparation is in the form of injection or oral administration.
[0040] In a second aspect of the present invention, a pharmaceutical composition is provided, the composition comprising:
[0041] (A) as the first active ingredient, radix quinquefolii or a radix quinquefolii extract;
[0042] (B) as a second active ingredient, an ingredient having an anti-glucocorticoid skin atrophy effect selected from the group consisting of vitamin A, vitamin C, vitamin E, collagen peptide, hyaluronic acid, apigenin, chlorogenic acid, ferulic acid, kojic acid, niacinamide, arbutin, or a combination thereof; and
[0043] (C) a pharmaceutically acceptable carrier or excipient.
[0044] In another preferred embodiment, the extract of Radix Glehniae is selected from the following group: a water extract of Radix Glehniae, an organic solvent extract of Radix Glehniae, or a combination thereof.
[0045] In another preferred embodiment, the organic solvent for extracting the active ingredient is selected from the following group: ethanol, petroleum ether, ethyl acetate or a combination thereof.
[0046] In the third aspect of the present invention, there is provided a use of the pharmaceutical composition according to the second aspect of the present invention for preparing a medicine, food, health product or cosmetic for treating skin atrophy.
[0047] In another preferred embodiment, the skin atrophy refers to skin atrophy caused by normal aging and / or skin atrophy caused by glucocorticoids.
[0048] In another preferred embodiment, the skin atrophy refers to skin atrophy caused by glucocorticoids.
[0049] In another preferred embodiment, the pharmaceutical composition is used for one or more purposes selected from the following group:
[0050] (i) Increase the mechanical strength of the skin;
[0051] (ii) Enhance the skin's ability to resist atrophy;
[0052] (iii) Restoration of epidermal cell proliferation capacity.
[0053] In another preferred embodiment, the increasing the mechanical strength of the skin includes increasing the level of skin extracellular matrix.
[0054] In another preferred embodiment, the extracellular matrix includes: collagen, elastin, glycosaminoglycan, proteoglycan, or a combination thereof.
[0055] In another preferred embodiment, the enhancing the anti-atrophy ability of epidermal cells comprises reducing the expression level of REDD1 protein.
[0056] In another preferred embodiment, the restoration of epidermal cell proliferation ability includes enhancing the expression level of Ki67 protein in skin cells.
[0057] In another preferred embodiment, the skin or epidermal cells are skin or epidermal cells treated with glucocorticoid.
[0058] In another preferred embodiment, the skin or epidermal cells are normal skin or epidermal cells, and / or atrophic skin or epidermal cells.
[0059] In a fourth aspect of the present invention, a kit is provided, comprising:
[0060] (1) A composition or preparation whose active ingredient is angelica sinensis or angelica sinensis extract;
[0061] (2) Glucocorticoids.
[0062] In another preferred embodiment, the glucocorticoid is selected from the following group: hydrocortisone, methylprednisolone, prednisone, dexamethasone, beclomethasone, betamethasone, hydrocortisone valerate, doprednisolone, prednicarbate, hydrocortisone butyrate, methylprednisolone acetate, triamcinolone acetonide, betamethasone valerate, mometasone furoate, fluticasone propionate, fluocinolone acetate, fluocinolone acetonide, clobetasol propionate, or a combination thereof.
[0063] In another preferred embodiment, the Xigui extract is selected from the following group: a water extract of Xigui, an organic solvent extract of Xigui, or a combination thereof.
[0064] In another preferred embodiment, the organic solvent for extracting the active ingredient is selected from the following group: ethanol, petroleum ether, ethyl acetate or a combination thereof.
[0065] In another preferred embodiment, the kit is used to improve skin atrophy caused by glucocorticoids.
[0066] In the fifth aspect of the present invention, a cosmetic or health care product is provided, wherein the cosmetic or health care product contains an extract of Xigui.
[0067] In another preferred embodiment, the Xigui extract is selected from the following group: a water extract of Xigui, an organic solvent extract of Xigui, or a combination thereof.
[0068] In another preferred embodiment, the organic solvent for extracting the active ingredient is selected from the following group: ethanol, petroleum ether, ethyl acetate or a combination thereof.
[0069] In a sixth aspect of the present invention, a method for promoting epidermal cell proliferation and / or reducing epidermal cell damage is provided, comprising the steps of:
[0070] The extract of Quinquefolia chinensis or the preparation containing the extract of Quinquefolia chinensis or the composition as described in the second aspect of the present invention is contacted with epidermal cells to promote the proliferation of epidermal cells and / or reduce the damage of epidermal cells.
[0071] In another preferred embodiment, the epidermal cells are epidermal cells of rodents.
[0072] In another preferred embodiment, the epidermal cells are mammalian epidermal cells.
[0073] In another preferred embodiment, the method is in vitro non-diagnostic and non-therapeutic.
[0074] In another preferred embodiment, the extract of Radix Glehniae is selected from the following group: a water extract of Radix Glehniae, an organic solvent extract of Radix Glehniae, or a combination thereof.
[0075] In another preferred embodiment, the organic solvent is selected from the following group: ethanol, petroleum ether, ethyl acetate or a combination thereof.
[0076] In a seventh aspect of the present invention, a method for enhancing the anti-atrophy function of epidermal cells is provided, wherein the Chinese medicine Xigui, an extract of Xigui or a preparation containing the extract of Xigui is administered to a subject in need thereof; and / or
[0077] A pharmaceutical composition as described in the second aspect of the present invention.
[0078] In another preferred embodiment, the extract of Radix Glehniae is selected from the following group: a water extract of Radix Glehniae, an organic solvent extract of Radix Glehniae, or a combination thereof.
[0079] In another preferred embodiment, the organic solvent is selected from the following group: ethanol, petroleum ether, ethyl acetate, n-butanol or a combination thereof.
[0080] In another preferred embodiment, the subject is a mammal, preferably a rodent or a primate, more preferably a mouse, a rat or a human.
[0081] In another preferred embodiment, the method is in vitro non-diagnostic and non-therapeutic.
[0082] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0083] Figure 1It is shown that in Example 3, the water extract of Radix Angelicae Pubescentis increases the epidermal thickness of mice with skin atrophy induced by glucocorticoid, * indicates P<0.05, ** indicates P<0.01, *** indicates P<0.001, scale bar=100 μm.
[0084] Figure 2 It is shown that in Example 4, the water extract and the ethyl acetate extract of Quinquefolia increased the dermal thickness of mice with skin atrophy induced by glucocorticoid, ** indicates P<0.01, *** indicates P<0.001, scale bar=100 μm.
[0085] Figure 3 It is shown that in Example 5, the water extract of Quinquefolia and the ethyl acetate extract of Quinquefolia increased the content of epidermal E-cadherin, * indicates P<0.05, ** indicates P<0.01, *** indicates P<0.001, scale bar=100 μm. DETAILED DESCRIPTION
[0086] After extensive and in-depth research, the inventor unexpectedly discovered that the traditional Chinese medicine Xigui can effectively improve the use of glucocorticoids, especially skin atrophy caused by topical glucocorticoids. On this basis, the present invention was completed.
[0087] Specifically, the inventors found that the water extract of the Chinese medicine Xigui can effectively improve the skin atrophy caused by topical glucocorticoids. The experiment of the present invention shows that Xigui can effectively increase the skin thickness (glycosaminoglycans, collagen) of the skin cells of mice with skin atrophy induced by glucocorticoids, restore the proliferation capacity of the epidermis (Ki67), and enhance the ability of epidermal cells (REDD1). Therefore, Xigui has broad prospects in the field of improving skin atrophy caused by topical glucocorticoids, and can be used to prepare auxiliary drugs or health products or cosmetics for treating skin atrophy caused by glucocorticoids.
[0088] the term
[0089] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0090] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0091] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0092] Skin atrophy
[0093] As used herein, "skin atrophy" refers to a pathological change in which one or more tissues of the epidermis, dermis or subcutaneous tissue are reduced and thinned, and specifically refers to skin aging caused by non-aging factors. It can be applied to people of any age group (0-80) with relevant needs.
[0094] As used herein, the "skin atrophy" may be caused by physical factors (including light, heat radiation, electrical radiation, nuclear radiation, wind, etc.), or chemical factors (such as corrosion by drugs or chemicals).
[0095] As used herein, the term "skin atrophy" refers to a decrease in the thickness of the dermis layer of the skin by ≥10%, ≥15% compared to the thickness of the dermis layer of the normal skin of the same subject (or the dermis layer of the normal skin of a subject of the same age group); preferably, a decrease of ≥25%; more preferably, a decrease of ≥40%, 50%, 55%, 60%, etc.;
[0096] The "skin atrophy" mentioned above refers to a decrease in the thickness of the epidermis of the skin by ≥10%, ≥15% compared to the thickness of the epidermis of the normal skin of the same subject (or the epidermis of the normal skin of a subject in the same age group); preferably, a decrease of ≥25%; more preferably, a decrease of ≥40%, 50%, 55%, 60%, etc.
[0097] The skin atrophy refers to that the amount of collagen in the extracellular matrix is reduced by 10% compared with the amount of collagen in the normal skin extracellular matrix of the same subject (or subject of the same age group); preferably, it is reduced by ≥15%; more preferably, it is reduced by ≥20%.
[0098] As used herein, the "skin atrophy" generally refers to the physiological atrophy of the skin induced by the use of glucocorticoids. Skin atrophy is also the most common adverse reaction of topical glucocorticoids.
[0099] As used herein, "topical glucocorticoids" refers to the use of topical glucocorticoid drugs in topical dosage forms (such as ointments, creams, etc.) and applied to partial skin areas by patients as needed to treat skin diseases.
[0100] Some representative skin atrophy markers or signs include (but are not limited to): extracellular matrix (such as glycosaminoglycans, collagen) content (a decrease in its expression indicates an increase in skin damage and a decrease in skin function), cell proliferation ability (a decrease in its expression indicates an increase in skin damage and a decrease in skin function), barrier function (a decrease in its expression indicates an increase in skin atrophy and a decrease in skin function), and skin anti-atrophy function (a decrease in its expression indicates an increase in skin atrophy and a decrease in skin function).
[0101] Active ingredient of the present invention and preparation method thereof
[0102] Return to the West
[0103] Chinese Angelica thibetica is the root of the plant Vicatia thibetica de Boiss. of the Apiaceae family, also known as Angelica thibetica, wild Angelica thibetica, etc., and is mainly distributed in places such as Yunnan, Sichuan, and Tibet. Chinese Angelica thibetica is warm in nature, sweet in taste, and slightly bitter, and has the effects of regulating menstruation, invigorating qi, and tonifying blood. Artificial cultivation is planted in some areas of Dali, Yunnan, and Chinese Angelica thibetica can be stewed with pig's feet, chicken, etc. as edible tonic dishes, and it is highly safe. At present, there is no report that it improves the skin atrophy induced by glucocorticoid.
[0104] As used herein, the terms "the extract of the present invention", "the active ingredient of the present invention", and "the composition or preparation of the present invention" are used interchangeably and all refer to the elm tree and its extracts extracted from the elm tree plant that have the function of regulating skin and improving skin function.
[0105] The extract of radix quinquefolii includes water extract of radix quinquefolii and organic extract of radix quinquefolii. Wherein, the organic extract of radix quinquefolii includes ethyl acetate extract.
[0106] In the present invention, the active ingredients capable of regulating and improving skin functions are extracted from radix scutellariae as a raw material.
[0107] In addition, although the effective parts that regulate skin function and improve skin function can come from the whole plant of the Umbelliferae family, which mainly includes roots, stems and other parts, they can also be extracted from the above-ground parts of the Umbelliferae family, such as branches, leaves and other parts.
[0108] As used herein, the term "extract" includes water-soluble and / or fat-soluble extracts. The term also includes alcohol extracts, ester extracts or water extracts.
[0109] According to analysis, the chemical components contained in the effective part of the present invention at least include substances selected from the following group: sugars, flavonoids, desphenolic acid, etc.
[0110] The method for preparing the extract of the plant of the genus Apiaceae of the present invention is not particularly limited. A water-soluble and / or fat-soluble extract can be obtained by conventional methods using the plant of the genus Apiaceae as a raw material.
[0111] In a preferred embodiment of the present invention, the preparation of the effective fraction is carried out by solvent extraction, extraction, and / or chromatography.
[0112] In the present invention, there is no particular limitation on the solvent used in the solvent extraction method, and representative examples include (but are not limited to): water, ethanol, methanol, acetone, ethyl acetate, or a mixed solvent of one or more solvents. The extraction times can be one or more.
[0113] In the present invention, there is no particular limitation on the solvent used in the solvent extraction method. Representative examples include (but are not limited to): n-butanol, ethyl acetate, dichloromethane, chloroform, cyclohexane, petroleum ether, or a mixture of one or more solvents. The extraction times may be one or more times;
[0114] In the present invention, there is no particular limitation on column chromatography, and representative examples include (but are not limited to): activated carbon, silica gel, reverse phase silica gel, macroporous resin, dextran gel or a combination of several thereof.
[0115] In a preferred embodiment of the present invention, the plant of the genus Apiaceae, the genus Apiaceae, is used as a raw material, and is extracted 1-5 times with water (or ethanol aqueous solution) of 2-10 times the weight of the medicinal material, and the water is recovered to obtain a water extract. The water extract is dissolved in 0.5-6 times the weight of ethanol (preferably 70-99% ethanol), the ethanol supernatant is set aside, the precipitate is dissolved in water, and then extracted with petroleum ether or ethyl acetate to obtain an ester extract. The extract is subjected to LC-MS analysis, and its main components are sugars, flavonoids, desphenolic acid, etc.
[0116] use
[0117] The composition or preparation of the present invention, in which the active ingredient is quinquefolius or quinquefolius extract, can be used to regulate skin function and improve skin atrophy.
[0118] Generally speaking, the compositions or preparations of the present invention can be used for one or more of the following purposes:
[0119] (i) increase the mechanical strength of the skin; and
[0120] (ii) enhancing the skin's ability to resist atrophy; and
[0121] (iii) Restoration of epidermal cell proliferation capacity.
[0122] In one embodiment, the composition or preparation is used to increase the thickness of the dermis.
[0123] In another embodiment, the composition or formulation is used to increase the thickness of the atrophied dermis by 10%, 15%, 20% or 25%.
[0124] In another embodiment, the composition or formulation is used to increase the thickness of the atrophied epidermis.
[0125] In another embodiment, the composition or formulation is used to increase the thickness of the atrophied epidermis by 10%, 15%, 20% or 25%.
[0126] In another embodiment, the composition or formulation can be used to increase the thickness of the dermis of atrophic skin to 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% of normal skin (of the same subject).
[0127] In another embodiment, the composition or formulation can be used to increase the thickness of the epidermis of atrophic skin to 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% of normal skin (of the same subject).
[0128] In another embodiment, the composition or formulation can be used to increase the amount of glycosaminoglycans in the extracellular matrix of atrophic skin to 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% of normal skin (of the same subject).
[0129] In another embodiment, the composition or formulation can be used to increase the amount of collagen in the extracellular matrix of atrophic skin to 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.9% of normal skin (of the same subject).
[0130] Pharmaceutical compositions and methods of administration
[0131] The present invention also provides a composition or preparation or product containing the active ingredient of the present invention, which can be used to improve skin atrophy induced by glucocorticoids (especially induced by topical glucocorticoids). Representative compositions or preparations or products include auxiliary drugs, health products, and cosmetics for treating skin atrophy caused by topical glucocorticoids.
[0132] The pharmaceutical composition of the present invention comprises:
[0133] (a) a water extract of quinquefolia or an organic solvent extract of quinquefolia as the first active ingredient; and / or
[0134] (b) as a second active ingredient, an ingredient having an anti-glucocorticoid skin atrophy effect selected from the group consisting of vitamin A, vitamin C, vitamin E, collagen peptide, hyaluronic acid, apigenin, chlorogenic acid, ferulic acid, kojic acid, niacinamide, arbutin, or a combination thereof; and
[0135] (c) a pharmaceutically acceptable carrier or excipient.
[0136] As used herein, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity (ie, improve glucocorticoid-induced skin atrophy) in humans and / or animals and is acceptable to humans and / or animals.
[0137] As used herein, the term "pharmaceutically acceptable" ingredients are suitable for use in humans and / or mammals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), i.e., substances with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
[0138] The pharmaceutical composition of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Usually, the pharmaceutical preparation should match the mode of administration. The dosage form of the pharmaceutical composition of the present invention is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent. For example, it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. The pharmaceutical composition is preferably manufactured under sterile conditions.
[0139] The effective amount of the active ingredient of the present invention may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's body weight, the patient's immune status, the route of administration, etc. Generally, when the active ingredient of the present invention is administered at a dose of about 0.00001g-6g / kg animal body weight (preferably 0.0001g-2.4g / kg animal body weight) per day, satisfactory results can be obtained. For example, depending on the urgency of the treatment situation, several divided doses may be administered per day, or the dose may be reduced proportionally.
[0140] Typically, when the pharmaceutical composition of the present invention is administered orally, the average daily dose for a 60 kg body weight subject (human) is usually 1-30 g, preferably 2-20 g, more preferably 5-12 g. The daily dose can be taken once, twice or multiple times.
[0141] The pharmaceutically acceptable carriers of the present invention include (but are not limited to): water, saline, liposomes, lipids, peptides, cellulose, nanogels, or combinations thereof. The choice of carrier should match the mode of administration, which are well known to those of ordinary skill in the art.
[0142] Compared with the prior art, the main advantages of the present invention include:
[0143] A) The present invention is the first to discover the use of the traditional Chinese medicine Xigui in improving glucocorticoid-induced (especially topical glucocorticoid-induced) skin atrophy.
[0144] B) The present invention is the first to discover the ability of Xigui to restore the skin function of mice.
[0145] C) The active ingredient of the present invention can be used to promote the proliferation of epidermal cells.
[0146] D) The active ingredients of the present invention are derived from Chinese herbal medicines and are safe and effective.
[0147] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0148] Example 1 Preparation of water extract and ethyl acetate extract samples of Xigui
[0149] Weigh 10 kg of dried roots of Xigui, crush them in a grinder, boil them with distilled water at 80°C for 3 times with a solid-liquid ratio of 1:10, and 90 minutes each time. Combine the extracts, concentrate under reduced pressure to obtain 4.55 kg of extract, with a calculated yield of 45.5%. Vacuum freeze-dry to obtain the water extract of Xigui.
[0150] Measure the extract of Xigui water extract and place it in a beaker. Add 6 times the volume of anhydrous ethanol to the beaker while stirring. After continuous mechanical stirring for 30 minutes, place it at 4°C and let it stand for 24 hours. The next day, stratification appeared in the beaker, with the upper layer being a light yellow clear liquid and the lower layer being a light yellow flocculent precipitate. Pour out most of the supernatant, add a small amount of anhydrous ethanol to the remaining precipitate, continue mechanical stirring for 30 minutes, and divide it into several 50mL centrifuge tubes, 4°C, 3000rpm, and centrifuge for 1 hour. After the centrifugation, pour out the supernatant and combine it with the previous supernatant, rotary evaporate to recover the solvent to the extract, and then freeze-dry. After the precipitate is dissolved in water, it is also rotary evaporated to the extract and freeze-dried. The supernatant is completely dissolved in deionized water and placed in a separatory funnel, and an equal volume of petroleum ether is added for extraction. After standing and stratifying, pour out the upper layer of petroleum ether, add an equal volume of petroleum ether for extraction, and repeat twice. Combine all the petroleum ether layer liquids, rotary evaporate and recover the solvent, and weigh to calculate the yield. An equal volume of ethyl acetate was added to the residual water layer for extraction. The extraction was repeated three times. The ethyl acetate layers were combined and the solvent was recovered by rotary evaporation to obtain the ethyl acetate extract of Xigui.
[0151] Example 2. Glucocorticoid-induced skin atrophy in mice and administration of water extract and ethyl acetate extract of Xigui
[0152] Female SPF C57BL / 6J mice aged 7-8 weeks (purchased from Vitallife) with a body weight of (20±2g) were randomly divided into 5 groups: blank control group, fluocinolone model group, fluocinolone + quinquefolium water extract (2.4g / kg) group, fluocinolone + quinquefolium ethyl acetate extract (45mg / kg) group, fluocinolone + chlorogenic acid (45mg / kg) (purchased from McLean) group, with 6 mice in each group. The mice were adapted to the experimental environment for 1 week. The hair on the back of the mice was shaved clean one day before the experiment to facilitate subsequent modeling and drug administration. Modeling and drug administration started on the same day. Except for the blank control group, 200μL (1μg / 100μg) of fluocinolone solution (dissolved in isopropanol) was applied to the back skin of mice in each group. The blank control group mice were applied with an equal volume of isopropanol every day, once every other day, and the cycle lasted for 14 days. Mice in the blank control group and fluocinolone acetonide model group were given 200 μL of drinking water by gavage, and mice in the fluocinolone acetonide + quinquefolius water extract group, fluocinolone acetonide + quinquefolius ethyl acetate extract and chlorogenic acid group were given 200 μL of drinking water by gavage once a day for 21 days.
[0153] On the 22nd day of the experiment, the mice were killed by cervical dislocation, and a part of the back skin tissue was embedded in paraffin and sliced, and another part of the back skin was quickly frozen and stored at -80°C, both of which were used in subsequent experiments.
[0154] Example 3. The water extract of Radix Angelicae Pubescentis increases the thickness of the epidermis of mice with glucocorticoid-induced skin atrophy
[0155] As described in Example 2., a mouse model was constructed and given water extract of Xigui, ethyl acetate extract of Xigui and chlorogenic acid, mice were killed and paraffin sections of the skin of mice of different groups were obtained, and glycosaminoglycans in the skin were stained using toluidine blue. The staining results were taken using a Nikon Ti2 inverted fluorescence microscope, and the images after the shooting were statistically analyzed using Image J software for epidermal thickness. Except for the fluocinolone acetonide model group, all data were compared with the fluocinolone acetonide model group to calculate significant differences (One-way ANOVA). Graph Pad was used for mapping, and the error bars were marked with the standard error of the mean (SEM).
[0156] The experimental results are as follows Figure 1 As shown in the figure, the thickness of the epidermis was statistically analyzed. Compared with the blank control group, the thickness of the epidermis of the mice in the fluocinolone acetonide model group was significantly reduced, *** indicates P < 0.001, scale bar = 100 μm. The Xigui water extract (2.4 g / kg) group and the chlorogenic acid group were able to increase the thickness of the epidermis, * indicates P < 0.05, ** indicates P < 0.01, scale bar = 100 μm.
[0157] Example 4. The water extract and ethyl acetate extract of radix quinquefolii increased the dermal thickness of the skin of mice with fluocinolone-induced skin atrophy
[0158] As described in Example 2., a mouse model was constructed and given water extract of Xigui, ethyl acetate extract of Xigui and chlorogenic acid, mice were killed and paraffin sections of mouse skin of different groups were obtained, and collagen in the skin was stained using Sirius red. The staining results were taken using a Nikon Ti2 inverted fluorescence microscope, and the images after shooting were statistically stained using Image J software. Except for the fluocinolone acetonide model group, all data were compared with the fluocinolone acetonide model group to calculate significant differences (One-way ANOVA). Graph Pad was used for mapping, and the error bars were marked with the standard error of the mean (SEM).
[0159] The experimental results are as follows Figure 2 As shown in the figure, the thickness of the dermis was statistically analyzed. Compared with the blank control group, the thickness of the dermis of the mice in the fluocinolone model group was significantly reduced, *** indicates P < 0.001, scale bar = 100 μm. Compared with the fluocinolone model group, the fluocinolone + guigui water extract (2.4 g / kg) group, the fluocinolone + guigui ethyl acetate extract (45 g / kg) group and the chlorogenic acid group were able to significantly increase the thickness of the dermis of the skin, ** indicates P < 0.01, *** indicates P < 0.001, scale bar = 100 μm.
[0160] Example 5. Xigui water extract improves epidermal cell barrier function in mice with fluocinolone-induced skin damage
[0161] The mouse model was constructed as described in Example 2. and the water extract of Xigui, ethyl acetate extract and chlorogenic acid were given, mice were killed and the skin of mice in different groups was obtained, and the E-cadherin protein in the skin of mice in different groups was immunofluorescently analyzed using E-cadherin antibody. The staining results were taken using a Nikon Ti2 inverted fluorescence microscope, and the images after shooting were statistically analyzed using Image J software for staining intensity. Except for the fluocinolone model group, all data were compared with the fluocinolone model group to calculate significant differences (One-way ANOVA). Graph Pad was used for mapping, and the error bars indicated the standard error of the mean (SEM).
[0162] The experimental results are as follows Figure 3 As shown in the figure, compared with the blank control group, the epidermal E-cadherin immunofluorescence staining of the mice in the fluocinolone model group was significantly reduced, * indicates P < 0.05, scale bar = 100 μm. The fluocinolone + guigui water extract (2.4 g / kg) group, fluocinolone + guigui ethyl acetate extract (45 g / kg) group and chlorogenic acid group can significantly increase the epidermal E-cadherin immunofluorescence staining of the skin compared with the fluocinolone model group, *** indicates P < 0.001 compared with the fluocinolone model group, scale bar = 100 μm.
[0163] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A use of an active ingredient, characterized in that: Used to prepare a preparation or composition, which is used for regulating skin function; wherein the active ingredient is quinquefolius or quinquefolius extract.
2. The use according to claim 1, characterized in that The skin atrophy described refers to skin atrophy caused by glucocorticoid.
3. The use according to claim 1, characterized in that The Xigui extract is selected from the following group: a water extract of Xigui, an organic solvent extract of Xigui, or a combination thereof.
4. The use according to claim 1, characterized in that The composition or preparation is used for one or more purposes selected from the following group: (i) increase the mechanical strength of the skin; and (ii) enhancing the skin's ability to resist atrophy; and (iii) Restoration of epidermal cell proliferation capacity.
5. The use according to claim 1, characterized in that The composition or preparation is in the form of injection or oral administration.
6. A pharmaceutical composition, characterized in that The composition contains: (A) as the first active ingredient, radix quinquefolii or a radix quinquefolii extract; (B) as a second active ingredient, an ingredient having an anti-glucocorticoid skin atrophy effect selected from the group consisting of vitamin A, vitamin C, vitamin E, collagen peptide, hyaluronic acid, apigenin, chlorogenic acid, ferulic acid, kojic acid, niacinamide, arbutin, or a combination thereof; and (C) a pharmaceutically acceptable carrier or excipient.
7. The pharmaceutical composition according to claim 6, characterized in that The extract of quince is selected from the following group: a water extract of quince, an organic solvent extract of quince, or a combination thereof.
8. Use of the pharmaceutical composition according to claim 6, characterized in that: Used for preparing medicines, foods, health products or cosmetics for treating skin atrophy.
9. A kit, characterized in that: include: (1) A composition or preparation whose active ingredient is angelica sinensis or angelica sinensis extract; (2) Glucocorticoids.
10. A method for promoting epidermal cell proliferation and / or reducing epidermal cell damage, characterized in that: Includes steps: The extract of Xigui or the preparation containing the extract of Xigui, or the composition as claimed in claim 6 is contacted with epidermal cells to promote the proliferation of epidermal cells and / or reduce the damage of epidermal cells.
